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Green eukaryotic microalgae are an attractive economic, and efficient, alternative to 
conventional recombinant protein expression systems and have the potential to 
revolutionize the biotechnology industry. Recent advancements in the genomic and 
proteomic techniques of microalgae have ushered tremendous efforts to optimize the 
“upstream” side of process design through the use of promoters, codon-optimization, and 
plasmid design. While the prospective for microalgae as a molecular farming platform is 
high, there are still a number of major obstacles, namely inconsistent transgene expression, 
that must be overcome before it can be implemented as a standard expression system.  
 
The supplementation of culture medium with sodium butyrate to enhance transgene 
expression in mammalian cells for higher protein yields has been studied for several 
decades. Despite the wealth of literature available on the role of sodium butyrate in 
inducing changes of the morphology, growth rate, and gene expression in mammalian and 
plant cells, there is little information documented on its effect on green microalgal cells. In 
this study we explore the changes in cell morphology, cell growth, and transgene expression 
of a recombinant anti-apoptotic Venus-Bcl-xL protein in microalgae Chlamydomonas 
reinhardtii (C. reinhardtii) cells induced by sodium butyrate supplementation, and investigate 
the prospective of combining the advantages of a genetically modified anti-apoptotic C. 
reinhardtii strain with the transgene enhancing effects of sodium butyrate.  
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We observed that concentrations of sodium butyrate above 250 mM were lethal for both 
the wild-type C. reinhardtii wall-deficient (CW 15+) UTEX 2337 strain and C. reinhardtii 
wall-deficient Venus-Bcl-xL (pRelax) strain. Concentrations of 50 mM and 100 mM 
induced phonotypical changes in the wild-type C. reinhardtii cell morphology induced 
apoptosis and inhibited cell growth. The difference in final cell density for cultures 
induced with 50 mM and 100 mM sodium butyrate from untreated cells averaged 5.79% 
and 62.92%, respectively. The anti-apoptotic pRelax C. reinhardtii strain showed significant 
signs of tolerance to apoptosis and cell growth inhibition at 50 mM and 100 mM sodium 
butyrate as cultures treated with 50 mM and 100 mM sodium butyrate were 75% and 78% 
less apoptotic than untreated pRelax cells, respectively, and difference in final cell density 
from untreated pRelax cells were -13.08% and 1.675%, respectively. The transgenic pRelax 
strain induced with 50 mM and 100 mM sodium butyrate showed substantial reduction in 
apoptotic behavior compared to untreated pRelax cells, indicating the possibility of up-
regulation of the recombinant anti-apoptotic Venus-Bcl-xL protein caused by sodium 
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In the early 80’s, the Food and Drug Administration (FDA) approved the clinical usage of 
recombinant human insulin from bacterium Escherichia coli (E. coli) for the treatment of 
diabetes. Since then, nearly 200 recombinant pharmaceuticals have entered the market 
with the approval for human use by the FDA and/or by the European Medicines Agency 
(EMEA) [1]. Most of the hosts used to produce these proteins are microbial cells such as 
bacteria and yeast. The difficulty of obtaining therapeutic human proteins from natural 
sources makes recombinant DNA technology an important tool for the effective and 
scalable production of pharmaceutical proteins [1]. 
 
The use of recombinant proteins has gained huge momentum in recent years, particularly 
in the biopharmaceutical industry, as advances in genomic and proteomic techniques 
enabled the development of more complex molecules and approaches. The number of 
recombinant protein pharmaceutical drugs is expected to surpass 200 over the next few 
years, all with potential to treat expanding human disorders such as diabetes, cancer, 
respiratory, cardiovascular and inflammation-related diseases, as well as rare diseases. The 
global market for protein pharmaceuticals exceeds $50 billion, with an average annual 
growth rate of almost 4% [2]. However, the development of any new protein-based drug is 
difficult with the requirements of such high capital investment and operating cost inherent 
in the production of these molecules. The costs of manufacturing a recombinant protein 
may constitute nearly 25% of its global sale figures [3]. The core element affecting the 
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process cost is the biological host used for the recombinant protein production, which 
creates great motivation to find cost-effective alternatives to current expression platforms 
[2].  
 
Current expression systems  
Although most of the FDA or EMEA approved recombinant pharmaceuticals are hosted by 
bacteria and yeast, no standard system exists for the efficient and cost-effective production 
of proteins on a commercial scale. Currently the inherent advantages of each system dictate 
its preference depending on the situation. For example, bacteria and yeast considered the 
most economic expression systems, because of their relatively inexpensive media 
components and operating costs [4]. They are also versatile due to the combination of a 
large database of physiological information and accessibility of advanced genetic tools. 
While the initial capital cost of fermentation and purification equipment is relatively 
expensive, the fermentation systems are simple and media costs are low.  
 
Despite the economic benefits of using bacteria expression systems, their application is 
limited due to their inability to perform post-transcriptional and post-translational 
modifications necessary for production of fully functional eukaryotic proteins [5]. While 
glycosylation is the most common post-translational modification, there are several others 
that play a critical role in biological activity, protein folding, tissue targeting, 
immunogenicity, solubility, and stability [1]. Although high levels of expression are 
achievable in bacteria, the expressed heterologous proteins tend to accumulate 
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intracellularly as insoluble inclusion bodies [6]. There are also difficulties downstream, as 
the presence of bacterial endotoxins and proteases makes purification difficult and can lead 
to adverse effects in humans [7]. 
 
Yeasts are as cost effective and fast as bacteria and cell cultures can reach a high density 
when grown in bioreactors. Approved protein products from yeast are produced solely in 
Saccharomyces cerevisiae (S. cerevisiae) [1]. Yeasts are capable of post-translational 
modification, and thus usually the expression host when the target protein requires a 
specific post-translational modification for biological activity [8]. While yeasts can perform 
glycosylation, the glycosylation process is different from that of higher eukaryotes and 
usually involves hyperglycosylation, which can lead to immunogenic responses in humans  
[9]. In both bacterial and yeast systems, overproduction of either eukaryotic or prokaryotic 
recombinant proteins has been found to trigger metabolic and conformational stress in the 
host cells [1]. The cells stress response can often lead to changes in protein processing 
resulting in useless products that failed to reach their native conformation [1]. In addition, 
bacteria and yeast expression systems fail to efficiently produce properly folded full-length 
molecules with sizes larger than 60 kDa, resulting in poor yields of more complex proteins 
[1, 4].  
 
Mammalian cell lines are currently the dominant system for the production of diagnostic 
and therapeutic proteins because of their capacity for proper protein folding, assembly and 
post-translational modification [10]. However, while these attributes are necessary for the 
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expression of fully functioning, complex molecules, such as therapeutic proteins, there are 
several major disadvantages that render mammalian cells inefficient as a standard 
recombinant pharmaceutical expression platform. Maintaining mammalian cell lines is 
difficult due to their inherent sensitivity and instability. In addition to extreme capital 
expenses, high media and protein purification costs cripple economic feasibility. Unlike 
bacteria and yeast, mammalian cells grow slowly, further hindering large-scale expression. 
The main danger of using mammalian cells is the potential of contamination of the 
isolated protein with disease-causing agents or oncogenic sequences [11]. Most of the 
therapeutic proteins approved thus far have been expressed in Chinese hamster ovary 
(CHO) cells, mainly for the robustness of the cells to grown in serum free media, protein-
free and chemically defined media [1]. Strictly controlling the media reduces risk of 
infection and immunogenicity, ultimately increasing the biosafety of the final protein 
products. Another major advantage of using CHO cells as an expression system is that 
recombinant protein can be secreted directly into the medium, which reduces the 
complications and costs of downstream purification [12]. Additional to CHO cells, mouse 
myeloma (NS0), baby hamster kidney (BHK), human embryonic kidney (HEK-293), human 
cervical cancer (HeLa) cells, and human-retina-derived (PERC6) cells have proved to be 
relatively good alternatives [13].  
 
Transgenic plants have the major advantage of scalability. Tobacco, for example, can be 
planted on thousands of acres. Thus, these plant expression systems can be grown on an 
agricultural scale. Additionally the production costs are much lower than bacterial, yeast, 
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and mammalian systems because of the plants’ inherent photosynthetic mechanisms. Like 
yeasts and mammalian bioreactors, plants are able to produce fully functional proteins. 
This combination of scalability and efficacy give terrestrial plants potential as a powerful 
platform for recombinant protein expression. However, a major drawback of this system is 
its low production rate. The time frame between initial transformation and having the 
appropriate amount of protein (mg to g) can be over two or three years. Additionally, 
expressing human therapeutics in plants is the threat of gene transfer to surrounding food 
crops [4]. However, the main disadvantage of using transgenic plants is related once again 
to post-translational modifications. Plant-specific glycosylation pathways introduced in 
recombinant proteins produce immunogenic responses in humans [9].  
 
The major prohibitive factors for a standard recombinant protein expression system are the 
high capital investment and production costs inherent in the current expression platforms. 
The high prices of protein drugs reflect the costs, which often make them inaccessible to 
many patients who are in need of the drugs. For example recombinant human 
Erythropoietin (EPO), used to treat anemia costs over $2 billion/kg. Enzyme replacement 
therapies such as for lysosomal storage diseases (LSD) represent in excess of $150,000/year 
per patient [13]. To make these crucial protein therapeutic treatments more widely 
accessible, a greater cost-effective, yet fully functional, expression system is needed as an 
economically viable alternative.  
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Potential of microalgae as a protein expression platform 
Eukaryotic microalgae are an attractive alternative to current models in use and have the 
potential to revolutionize biotechnology. The growth rate of algae is much faster compared 
to terrestrial plants. For example, microalgae like Chlamydomonas reinhardtii (C. reinhardtii) 
double cell number in approximately 8 hours under a 12-hour light, 12-hour dark regime. 
Time from initial transformation to protein production can be as little as six weeks and 
scale-up from flasks to a commercially viable scale can be just a few months [4].  Like 
plants, the algae can be cultivated at low productions costs as they require only water and 
nutrients, but there is no risk for transgene flow to food crops as the algae can be 
contained in photo bioreactor cultures. Additionally, microalgae’s protein content ranges 
from 50 – 70% of its fresh weight, which is a much higher percentage than the choicest 
edible parts of any higher plant or animal [14]. 
 
The unicellular green microalgae C. reinhardtii is a fantastic model organism for the study 
of a broad range of biological uncertainties in areas such as flagellar function, 
photobiology, and photosynthesis research [15, 16, 17, 18]. The nuclear, chloroplast, and 
mitochondrial genomes have been fully sequenced and can be transformed [19]. It can 
reproduce sexually or asexually and can grow photoautotrophically, heterotrophically or 
mixotrophically. The completion of the Chlamydomonas genome-sequencing project in 
2007, provided new insights into the evolution of photosynthetic eukaryotes, and paved 




The chloroplast organelle of plant and eukaryotic microalgal cells, like C. reinhardtii, hosts 
many important biosynthetic pathways, such as photosynthesis, and also serves as a storage 
compartment [22]. C. reinhardtii has one large chloroplast that fills approximately 40% of 
the cell by volume. The chloroplast genome is a 203 kb circular molecule and encodes for 
approximately 100 genes [23]. Each chloroplast has about 80 identical copies of each 
genome. Inherently, the chloroplast is capable of accumulating substantial amounts of 
membrane proteins (i.e. photosystems I and II) and soluble proteins (i.e. enzymes like 
RuBisCO) along with other macromolecules such as chlorophylls, carotenoids, starch and 
lipids. The intrinsic function of the chloroplast makes it an attractive platform from a 
recombinant-genetics perspective [22].  
 
In a recent study on recombinant antibody production, the cost of production per gram of 
functional antibody was only US $0.002 in microalgae, while $150 and $0.05 in 
mammalian and plant expression systems, respectively [24]. Additionally, microalgae 
contain all the advantages of post-translational and post-transcriptional modifications and 
are efficient at folding and producing complex, functional proteins. Algae are also generally 
regarded as safe (GRAS), which make them potentially valuable for oral delivery vehicle of 
therapeutic proteins with little to no purification.  
 
However, despite its rapid growth and high biomass production at low cost, prospects for 
microalgae as an efficient production platform for recombinant proteins as 
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biopharmaceuticals, has been severely hampered by the very low expression levels usually 






















CHAPTER ONE: GENETIC ENGINEERING OF MICROALGAE 
CHLAMYDOMONAS REINHARDTII  
 
Although recombinant protein expression at commercially viable levels has only been 
reported for expression from the chloroplast genome, both the nuclear and mitochondrial 
genomes have achieved successful recombinant protein expression [25].  
 
BACKGROUND 
There are several reasons that the chloroplast may be considered more advantageous than 
the nucleus in expressing transgenes for recombinant products [26]. Transformation in the 
chloroplast, in contrast to transformation in the nucleus, is almost exclusively executed 
through homologous recombination. Thus, the transgene inserted into the plastome can 
be site-specific leading to precise and predictable manipulation. Nuclear transformation is 
primarily performed by random insertion through non-homologous end joining, which can 
lead to many undesirable side effects, because genes coding for regulatory elements can be 
disrupted [27]. Alternatively, homologous recombination through chloroplast 
transformation enables precise targeting of “silent sites,” or regions void of any known 
coding sequences [28]. While, the highest reported protein expression level in the 
chloroplast is slightly over 10% total soluble protein (TSP), the majority of yields average 
around 5% TSP [29, 30]. In contrast, an expression level of 0.2% TSP achieved from 
nuclear expression is relatively high [21].  
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The potential and limitation of genetic engineering the nuclear genome 
Despite the low yields of recombinant protein expression from nuclear expression, the 
possibilities for post-transcriptional, post-translational modifications, and post-translational 
targeting to specific intracellular organelles make nuclear expression necessary for complex 
protein expression [25]. While the reasons for low nuclear expression are still poorly 
understood, positional effects, RNA silencing, a prohibitively compact chromatin 
structure, and non-conventional epigenetic effects have been anticipated as possible reasons 
[25].  
 
The impact of promoters 
For high recombinant protein yields, the plasmid-construct design should reflect an 
optimal system from all stages of gene expression, from gene transcription to protein 
stability. The most important elements for high-level transcription are the promoters and 
5’/3’ regulatory untranslated regions (UTRs) [31]. In general, functional promoters 
regulate transcription, 5’ UTR mediate mRNA stabilization, and translation initiation, and 
3’-UTR mediate stability and act in the termination of transcription [32]. Improvements in 
recombinant protein expression in algae can be largely credited to advancements in 
identifying functional promoter sequences. Flanking the transgene of interest with a proper 
promoter, and its respective 5’/3’ UTRs, is important for high-level transcription. These 
sequences are distinctive depending on different microalgal strains and genes. Even within 
the cell the promoter sequences are different with respect to cell localization [32].  
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Codon bias optimization 
Along with promoters and 5’/3’ UTR sequences, codon dependency is an important 
limiting factor for the high expression of transgenic protein in microalgae. Different 
organisms can use certain codons more frequently than others, leading to a contrary bias in 
codon usage between host cells. This causes shifts in tRNA abundance potentially leading 
to translational stalling, premature translation termination, translation frame shifting and 
amino acid misincorporation [33]. An example of such codon dependency can be found in 
C. reinhardtii, which has an extremely high GC content (~61%) [34]. It has also been 
observed that codons containing adenine or thiamine nucleotides in the third position 
favored over those with guanine or cytosine [35]. In 2002 Franklin, et al, tested the effects 
of codon dependency in the C. reinhardtii chloroplast by developing a gene encoding green 
fluorescent protein (GFP) de novo, which has been codon optimized to the C. reinhardtii 
chloroplast genome. Protein expression levels of codon-optimized GFP was compared to 
that of a non-optimized GFP, both under the control of an rbcL promoter and 5’/3’ UTRs. 
A 80-fold increase in GFP accumulation was observed in the case where C. reinhardtii was 
transformed with codon-optimized GFP [36].  
 
Genetic transformation of cell wall-deficient C. reinhardtii 
The removal of the cell walls from C. reinhardtii wild-type strains significantly increases the 
number of successful transformants. The mating of mating type plus (mt+) with mating 
type minus (mt-) gametes of C. reinhardtii creates cell wall-deficient strains, by the release of 
enzymes that cause cell wall degradation during flagellar interaction [37].  There are several 
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techniques developed for the delivery of DNA to the target microalgal genomes that are 
still being applied and studied in recent research. Although these transformation methods 
are done with wall-deficient strains, the efficiencies successful for transformants are still 
very low [25].  
 
Glass beads method 
Transformation by glass beads is a simple and effective technique that involves agitating 
wall-deficient cells with linearized, recombinant DNA and sterile glass beads. Although the 
intensity of the agitation affects the viability of the transformed cells, efficiencies of 103 
transformants/μg DNA for nuclear transformation and 50 transformants/μg DNA for 
chloroplast transformation were observed [38, 39].  
 
Particle bombardment 
The particle bombardment method has been shown to be effective for the stable 
transformation of the nuclear and chloroplast genomes of C. reinhardtii [38, 40]. The 
technique involves the bombardment of target algae cells with metallic particles, usually 
gold or tungsten, which are coated in DNA. The transformation efficiency can be especially 
low due to the fatal effect of the bombard on the cells. However, it remains to be the most 
effective method for transformation of the chloroplast, because it allows the penetration of 
the recombinant DNA through both the cell membrane and chloroplast membrane, for 
successful integration [41]. The method is significantly more expensive, because it requires 
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specialized equipment, and thus less preferred over glass beads or electroporation methods 
for nuclear transformation.  
 
Electroporation 
Transformation by electroporation is two orders of magnitude higher in transformation 
efficiency compared to the glass beads method [42]. It exposes the cell walls to high 
intensity electrical field pulses that induce macromolecular uptake and disrupt lipid 
bilayers, leading to efficient molecular transport across the plasma membrane [43, 44]. 
Electroporation only requires relatively simple equipment, compared to particle 
bombardment, but is dependent on important parameters including field strength, pulse 
length, medium composition, temperature, and membrane characteristics [42, 43].  
 
Agrobacterium tumefaciens 
Another method of delivering recombinant DNA is by transformation with tumor-
inducing Agrobacterium tumefaciens [25]. While this method has been mainly used for the 
modification of plant cells, C. reinhardtii has been successfully transformed by this method 
with recorded transformation efficiencies that are fifty times greater than the glass-beads 
method [45]. Although, transformation of microalgae with Agrobacterium is still a field in its 




MATERIALS & METHODS  
pVenus and pRelax plasmid overview: 
The two vectors used to transform C. reinhardtii wall-deficient strain UTEX 2337 (CW 15+) 
are outlined below (see Figures 1a and 1b). Both vectors have been codon-optimized to the 
nuclear genome. 
 
Figure 1a: Vector map of pVenus plasmid with Pvu1 restriction enzyme sites. Expected 




Figure 1b: Vector map of pVenus-Bcl-xL (pRelax) plasmid with PvuI restriction enzyme 
sites. Expected band lengths (bp): 2929, 2484, 1045. 
 
Both the pVenus and pRelax vector were designed by Rosenberg, et al [46]. The Venus 
protein is a fluorescent reporter, which has been shown to have higher fluorescence than a 
similar fluorescent marker yellow fluorescent protein. In the case of the pRelax plasmid, 
the Venus is immediately upstream of the anti-apoptotic Bcl-xL gene, which is ultimately 
translated into a Venus-Bcl-xL fusion protein [47]. The Bcl-xL protein has been shown to 
prevent programmed cell death in a number of mammalian and plant cells [48, 49]. The 
plasmids are designed to have the HSP70 (heat shock protein 70) promoter fused upstream 
of a RBCS2 (rubisco) promoter, which has been shown to significantly improve driving 
transgene expression and transformation efficiency in C. reinhardtii [50, 51]. Both plasmids 
also have a bacterial resistance gene ble, which is needed for selecting successfully 
transformed colonies.  
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pVenus and pRelax Plasmid DNA Purification: 
Glycerol stocks of pVenus and pRelax plasmids were received from Synaptic Research LLC 
in Baltimore, MD. Glycerol stocks were lightly brushed using 200 μL pipet tips, and pipet 
tips were dispensed into 3 mL of Luria Broth medium (Sigma-Aldrich, St. Louis, MO). 3 
mL of bacterial culture, DH5α, were grown overnight for 16 hours. 1 mL of each culture 
were pipetted and harvested by centrifugation for subsequent DNA plasmid purification. 
Remaining 2 mL of each bacterial culture were stored at 4 °C to be further scaled up.  
 
DNA plasmids were purified using a QIAprep Spin Miniprep Kit (QIAGEN, USA Cat# 
27104). Purified DNA samples for pVenus and pRelax were eluted into 1.5 mL 
microcentrifuge tubes and stored at -20 °C for further restriction enzyme digest analysis.  
 
Restriction Enzyme Diagnostic Digest of pVenus and pRelax Plasmids  
Purified DNA plasmids from mini-prep were analyzed by restriction enzyme digest to 
confirm presence of complete and proper plasmid. 30 μL of reaction mix was prepared for 
each sample as follows: 1 μL PvuI restriction enzyme, 3 μL 10x NEB 3.1 buffer, 3 μL 10x 
BSA, 2 μg pVenus/pRelax plasmid (23 μL). Each sample was incubated at 37 °C for 2-3 
hours. 
 
After incubation, samples were run in a 1% (w/v) electrophoretic gel prepared by 0.5 g of 
Ultra Pure Agarose (Invitrogen, USA #16500500), 1 μL of Ethidium Bromide (10 
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mg/mL), and 50 mL of DI water. Gene Ruler™ 1 kb DNA ladder (Fisher Scientific®, 
Pittsburg, PA) was used as a standard measure.  
 
Nuclear transformation of C. reinhardtii wall-deficient strain UTEX 2337 (CW 15+)  
Plasmid DNA Purification and Preparation 
A culture of bacteria DH5α was scaled up to 50 mL of LB medium and grown overnight 
for 16 hours. Cells were harvest by centrifugation at 6,000 x g at 4 °C for 10 min in a 5417-
C Eppendorf microcentrifuge. DNA plasmids were purified by using HiSpeed Plasmid 
Midiprep Kit (QIAGEN, USA # 12643). Purified DNA samples for pVenus and pRelax 
were eluted into 1.5 mL microcentrifuge tubes and stored at -20 °C to be used for 
transformation.   
 
Before transformation, plasmid DNA must be linearized to be properly inserted into the 
nuclear genome. Total 80 μL of reaction mix was prepared for each sample as follows: 1 μL 
BamHI HF restriction enzyme, 8 μL Cutsmart buffer, 8 μL 10x BSA, 2 μg pVenus/pRelax 
plasmid (63 μL). Each sample was incubated at 37 °C for 2-3 hours for linearization and 
subsequently used for transformation. 
 
Transformation by Glass Beads Method 
Glass beads method transformation protocol was received from Wipawee Dejtisakdi at 
University of Maryland Baltimore County. C. reinhardtii wall-deficient strain UTEX 2337 
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(CW 15+) was grown in 50 mL of Tris-Acetate-Phosphate (TAP) medium to a cell density of 
~5 x 106 cells/mL. Cells were pelleted by centrifugation at 6,000 x g and resuspended in 5 
mL of TAP medium to achieve a cell density of ~50 x 106 cells/mL. 300 μL of cells was 
added to a 1.5 mL microcentrifuge tube to which 2 μg of linearized DNA had already been 
added. 0.4 mm glass beads were from Sigma (St. Louis, MO Cat# 120M5327V) and were 
pre-washed and sterilized in acid. 400 μg of acid-washed glass beads were then added to 
each microcentrifuge tube and each sample was vortexed at top speed for 15 seconds. The 
solution was carefully pipetted from the beads and spread onto TAP + 1 mg/L bleocin 
plates for selection. Plates were air-dried in the hood and placed under low light (200 
μEinstein) and monitored for colony formation for 7 days.  
 
Transformation by Electroporation 
Electroporation transformation protocol was from Shimogawara, et al [42]. C. reinhardtii 
wall-deficient strain UTEX 2337 (CW 15+) was grown in 200 mL of TAP to a density of 1-3 
x 106 cells/mL. Cells were chilled on ice for 10 min and then subsequently centrifuged at 
2,000 x g for 5 min at 4 °C. After the supernatant was disposed, the pelleted cells were 
resuspended with 1 mL of TAP + 60 mM Sucrose (Sigma, St. Louis, MO, SKU# 252603) 
to a density of 4 x 108 cells/mL on ice. 250 mL of resuspended cells were mixed on ice with 
1 μg of plasmid DNA in a 4 mm chilled cuvette (Bio-Rad, Cat# 165-2081) and 
subsequently incubated for 5 min in 16 °C water bath. Electroporation was performed 
using a Bio-Rad Total Cell system, BioRad Gene Pulser II (Bio-Rad, USA), with the 
following parameters: one pulse, 0.8 kV, 25 mF, no resistance, and time constant of 5-6 
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msec. After electroporation, the cuvettes were incubated at room temperature for 10 min. 
Cells were gently resuspended and transferred to a 50 mL sterile disposable tube. The cells 
were allowed to recover for 24 hr by incubating in 10 mL of TAP + 60 mM Sucrose under 
low light conditions. On the second day, the cells were pelleted at 2,000 x g for 1 min at 
room temperature and resuspended in 2 mL of TAP with 1 mg/L bleocin antibiotic for 
selection. 500 μL of cells were plated onto TAP + 1.5 mg/L bleocin agar plates and allowed 
to recover under low light conditions. The plates were monitored for 1 to 2 weeks to see 
colony formation in the case of successful transformation.  
RESULTS & DISCUSSION 
pVenus and pRelax Plasmid DNA Purification from Glycerol Stocks 
Plasmid DNA was purified and analyzed by a restriction enzyme digest diagnostic. Enzyme 
PvuI was used because it digested the plasmid at three sites, with a clear comparison of 
band lengths between the pVenus and pRelax plasmids. The results of the diagnostic digest 




Figure 2: Diagnostic digest analysis of pVenus and pRelax plasmids. From left to right: 
M, 1 kb marker; V(-), undigested pVenus plasmid; V(+), digested pVenus plasmid; R(-), 
undigested pRelax plasmid; R(+), digested pRelax plasmid.  
 
The expected sizes of fragments using restriction enzyme, PvuI, were 2929, 1777, and 1045 
bp for pVenus and 2929, 2484, and 1045 bp for pRelax. As shown in Figure X above, the 
diagnostic digest shows a band at the expected sizes for each respective plasmid. The digest 
confirms that the plasmid purification was successful and also that the plasmids from the 
glycerol stocks were in fact pVenus and pRelax. With sufficient quantities of plasmid DNA 
for pVenus and pRelax now purified and readily available, we were able to proceed with 
attempting a nuclear transformation of C. reinhardtii. 
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Nuclear transformation of C. reinhardtii wall-deficient strain UTEX 2337  
Transformation of C. reinhardtii wall-deficient strain UTEX 2337 (CW 15+) with the glass 
beads protocol failed to produce any viable transformants (results not shown). The 
electroporation method was performed twice, on separate occasions. After growing for 1 to 
2 weeks in low-light conditions, the plates from the first electroporation transformation 




Figure 3: C. reinhardtii wall-deficient strain (CW 15+) UTEX 2337 transformants by 
electroporation (first run) - Day 7. Electroporation parameters: one pulse, 0.8 kV, 25 mF, 
no resistance, and time constant of 5-6 msec. (A) – (B) are pVenus transformants. (C) – (D) 
are pRelax transformants.  
 
The plates labeled pVenus#2, pRelax#1, and pRelax#2 appear to be contaminated with 
bacteria, despite the plates having bleocin antibiotic. No plates have sign of any viable algal 
cells or colonies. 
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The electroporation method was repeated with a higher density of cells transformed, and 
this time a double restriction enzyme digest using NotI and ApaI sites was performed to 
linearize plasmid DNA. Plates were observed for 7 days (see Figures 4a and 4b).  
 
       
Figure 4a: C. reinhardtii wall-deficient strain (CW 15+) UTEX 2337 transformants by 
electroporation (second run) - Day 2. Electroporation parameters: one pulse, 0.8 kV, 25 
mF, no resistance, and time constant of 5-6 msec. (A) – (C) pVenus transformations 
labeled pVenus#1, pVenus #2, and pVenus#3, respectively. (D) – (F) pRelax transformants 












Figure 4b: C. reinhardtii wall-deficient strain (CW 15+) UTEX 2337 transformants by 
electroporation (second run) - Day 7.  (A) – (C) pVenus transformations labeled 
pVenus#1, pVenus #2, and pVenus#3, respectively. (D) – (F) pRelax transformants labeled 
pRelax#1, pRelax#2, and pRelax #3, respectively. (F) Positive control with UTEX 2337 on 
TAP. (G) Negative control with UTEX 2336 on TAP + bleocin.  
 
As shown in Figure 4b above, plates labeled pVenus#3, pRelax#2, and pRelax #3 show no 
sign of viable cells or colonies after 7 days. Positive control of UTEX 2337 show viability of 
un-transformed cells, and negative control shows the efficacy of the bleocin antibiotic for 
successful transformants selection purposes. Plates labeled pVenus#1, pVenus#2, and 
pRelax#1 appear to have viable cells, however it was impossible to select for individual 
colonies. A streak of cells was taken from each of the plates with viable cells, and 
suspended in 10 mL of TAP media + 1 mg/L bleocin to see if the cells were in fact resistant 




Microalgae are a promising alternative to conventional recombinant protein expression 
systems, which are vastly expensive and limited in functionality. While there is great 
potential for microalgae as a molecular farming platform, inconsistent transgene expression 
hinder microalgae from becoming a standard expression system. The nuclear genome is 
especially promising for its ability for post-transcriptional, post-translational modifications, 
and post-translational targeting to specific intracellular organelles, which are necessary for 
complex protein expression. However, like most eukaryotic organisms, microalgae suffer 
from unpredictable expression of introduced transgenes as transgenes inserted into the 
nuclear genome are frequently silenced.  
 
Here we attempted the insertion of transgenes into the nuclear genome of C. reinhardtii 
wall-deficient strain UTEX 2337 (CW 15+) using a glass beads method and electroporation 
method. Transformations with either method failed to yield any positive transformants or 
results. The failure to produce any successful transformants with the pVenus and pRelax 
vector may very well be due to an error in the protocol, or execution of the protocol. 
However, the electroporation method was done twice, both times meticulously, and with 
several duplicate samples to amplify the possibility of successful transformants. This set of 
experiments, provided important experiences highlighting the difficulty of successfully 
introducing transgenes into the nuclear genome of C. reinhardtii and yielding high nuclear 
expression. These difficulties were present, despite the use of strong promoters and good 
plasmid design. Optimization of “upstream” parameters are a powerful way to improve 
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transgene expression in microalgae and holds great potential in re-defining microalgae’s 
role in the recombinant biopharmaceutical industry. However, the results of this study 
show a need for a coupled effort to optimize the “downstream” side of the process to 
further realize the potential of microalgae systems. It is with this intention that the 
supplementation of culture medium with sodium butyrate to induce gene expression is 




















CHAPTER TWO: THE EFFECT OF SODIUM BUTYRATE ON MICROALGAE 
CHLAMYDOMONAS REINHARDTII 
 
One of the main objectives in molecular farming is the achievement of high recombinant 
protein production. While the mechanism of gene silencing is not clearly understood, the 
role of chromatin structure has been identified as an influencing factor. Two types of gene 
silencing are distinguished: transcriptional silencing, which involves the inhibition of in 
transgene transcription, and post-transcriptional gene silencing, which is characterized by 
the rapid degradation of initially synthesized transcripts [51]. Many avenues have been 
examined in the “upstream” side of process engineering and design, such as codon 
optimization, promoters, transformation-associated genotypic modifications, enhancer 
elements, regulatory mechanisms, and sensitivity to proteases and protein localization. 
While these factors that can be precisely controlled through the design of the plasmid-
construct, there are still many unpredictable factors that inhibit transgene expression. 
Additional to these upstream parameters, the cultivation operating regulations, such as 
mixing, illumination, media composition, pH, temperature, and nutrient concentration, 
can greatly influence protein yields [31]. Sodium butyrate has been well documented to 
arrest cell division and increase gene expression in both mammalian and plant systems 
[52]. These changes present opportunities for higher production levels of the protein of 
interest, while reducing the quantity of cells needed to more manageable densities and 




There is a wealth of research and literature on the effect of sodium butyrate on mammalian 
and plant cells in culture. Sodium butyrate has been shown to cause a variety of 
morphological and functional changes in these cells, often related to cell shape, cell 
growth, and gene expression. It is also known to induce apoptosis in some cell lines [53]. 
Butyric acid is a 4-carbon fatty acid that is naturally formed in the body, but is toxic to 
human cells in culture at concentrations above 10 mM [54].  
 
Sodium butyrate induces cell-growth arrest, apoptosis, and morphological changes in 
mammalian and plant cells in culture 
Decades of research has shown that sodium butyrate arrests cells at the G1 to S phase 
transition point of the cell cycle for many mammalian cells [52]. A study in 1973 by Wright 
showed that CHO cells grown in the presence of sodium butyrate decrease their growth 
rate, increase in length, and have a tendency to grow in a monolayer [55]. The treated cells 
had a distinctly longer and more “fibroblast-like” characteristic compared to cells cultured 
in the absence of sodium butyrate. The doubling times were increased by nearly 100% in 
the presence of 0.5 mM and 1.0 mM sodium butyrate. These morphological and cell 
growth changes were observed to be slowly reversible after the culture medium was 
replaced with fresh growth medium. An impressive review by Prasad and Sinha in 1976, 
documents the effects of sodium butyrate on the mammalian cells in cultures. The report 
goes to show that sodium butyrate reversibly inhibits the division of mouse neuroblastoma 
cells and increases the intracellular level of adenosine 3’, 5’-cyclic monophosphate (cAMP). 
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The effect was slightly different on human neuroblastoma cells as it caused extensive cell 
death and induced neurites along with inhibiting cell growth. The growth rate, and 
morphology of human tumor neuroblasts or human tumor astrocytes were unaffected at 
concentrations under 0.5 mM, but apoptotic at higher concentrations. The normally 
round HeLa cells become spiky in the presence of 2.5 – 5 mM sodium butyrate. The 
growth rate of rat XC sarcoma line cells was not affected by 1.0 mM sodium butyrate, but 
cells were observed to be considerably flattened and cellular outline unclear. However, 
concentrations of 5.0 mM produced no effect on morphology, growth, or differentiation 
on rat mammary tumor cells or rat myoblast cells. Growth rates of slow growing hepatoma 
(8999) cells were unaffected by 1.0 mM sodium butyrate, but growth rates of fast growing 
hepatoma (3924 A) cells were inhibited. Sodium butyrate in concentration of 2.5 mM was 
observed to inhibit cell division of monkey or calf kidney epithelial cells, and chick embryo 
cells, with no changes in their morphologies [54].  
 
The effect of sodium butyrate on plant systems is not as extensively studied as mammalian 
cells. A 1988 study with Jerusalem artichoke (Helianthus tuberosus L.) tuber explants, 
showed that sodium butyrate inhibited DNA replication and cell division [56]. In 
transgenic tomato (Lycopersicon esculentum Mill.) cells, cell growth was hindered at 
concentration of 5 – 10 mM sodium butyrate and arrested at 20 mM [57].  
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Sodium butyrate induces transgene expression in mammalian and plant cells 
Throughout the past several decades, sodium butyrate has also been shown to induce 
enhanced gene expression in a variety of mammalian cells. In 1983, Gorman, et al., showed 
up to a 7.5 fold increase in recombinant chloramphenicol acetyltransferases gene with 
HeLA and monkey kidney CV-1 cells induced by sodium butyrate [58]. Nearly a decade 
later, sodium butyrate was used to enhance the expression levels of nine different tissue 
plasminogen activator analogues in CHO cells. Inductions in the presence of sodium 
butyrate induced a 2 – 9 fold increase in the production of these nine recombinant 
proteins, on average [52]. In 1995, Kooistra, et al., discovered that stimulation of tissue-type 
plasminogen activator (t-PA) expression in human umbilical vein endothelial cells 
(HUVEC) by sodium butyrate induction was related with histone H4 acetylation [59].  
 
Interestingly, sodium butyrate has a similar effect on plant cells as well. A relatively recent 
study in 2001 by Chung, et al., showed a 143% increase in recombinant rotavirus VP6 in 
transgenic tomato (Lycopersicon esculentum Mill.) cells treated with sodium butyrate [57]. 
Additionally, analysis of total protein extracts of the sodium butyrate-supplemented 
transgenic tomato cells showed the up-regulation of 14 proteins and down-regulation of 7 
proteins. Interestingly, 4 of the up-regulated proteins were similar to proteins specific for 
cell-growth arrest while 3 down-regulated proteins matched cell division proteins. One of 
the up-regulated proteins matched a histone acetyltransferase type B catalytic subunit, and 
two of the down-regulated proteins resembled histone deacetylases, indicating sodium 
butyrate behaves similarly to a histone deacetyltransferase inhibitor.  A similar study was 
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conducted in 1990 in alfalfa (Medicago sativa) cells. The addition of sodium butyrate to the 
culture revealed that butyrate was metabolized, which lead directly to histone acetylation  
[60].  
 
Although the exact mechanism behind enhanced gene expression by sodium butyrate 
induction is still ambiguous, it is clear from previous literature and research that sodium 
butyrate is capable of initiating changes in chromatin structure as a result of 
hyperacetylation of histones [52].  
 
The role of histone acetylation in gene expression 
Nuclear DNA exists as a system of chromatin structures, resulting in compaction of the 
nuclear DNA about 10,000-fold. This orderly packing of DNA in in the nucleus plays an 
important role in the functional aspects of gene regulation [61]. A repeating structure of 
nucleosome core particles makes up the chromatin. 146 bp of DNA wrap around the 
histone octamer core of the nucleosome, while linker DNA of varying lengths join each 
nucleosome. There are four core histone domains H3, H4, H2A, and H2B, each with a 
basic N-terminal domain, a histone fold, and a C-terminal domain [62]. The so called N-
terminal tails of the core histones consist of 16 – 44 amino acids and are the sites of 
various post-synthetic modifications, which include acetylation, phosphorylation, 
methylation, ubiquitination, glycosylation, and ADP-ribosylation [61]. Acetylation of the 
nucleosome inhibits the higher order folding of the chromatin, preserves the unfolded 
structure of the transcribed nucleosome, and induces the solubility of chromatin, 
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ultimately leading to increased exposure of DNA to transcription factor binding [61, 63, 
64].  
 
In 1977, Allfrey, et al., first discovered the correlation between high levels of histone 
acetylation and gene transcription [65]. Within a decade, it was observed that histone 
acetylation is dynamic; meaning a localized shift in the dynamic equilibrium between 
histone acetyltransferases and histone deacetyltransferases activities towards acetylation 
results in a localization of highly acetylated chromatin on or near transcriptionally active 
genes [66, 67]. The roles of H3 and H4 core histones have been studied extensively by 
using specific antibodies in the past several decades, confirming the correlation between 
high acetylation and gene transcription [68].  
 
Histone acetylation in Chlamydomonas reinhardtii 
In unicellular green algae C. reinhardtii, the main target of acetylation is histone H3. Half-
life for acetylation of H3 was found to be 1.5 – 3 min, when dynamically acetylated to 30%  
[69]. In contrast, histone acetylation has a turnover half-life of 3 – 30 min in animal cells 
and 30 – 300 min in yeast [69]. The majority of studies of histone acetylation have been 
performed in animal cells, in fungi like S. cerevisiae or protists like Tetrahymena, where the 
H4 histone is the primary target of histone acetylation. In higher plants, histone H3 is the 
predominant target of histone acetylation; especially those localized in transcriptionally 
active chromatin domains, followed by histone H4. However, in C. reinhardtii, the 
difference is drastic and steady-state levels of multi-acetylated H3 are very high [69].  
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Mammalian Bcl-xL protein and its role in inhibiting cell death 
The Bcl-xL protein is a member of the B-cell lymphoma (Bcl) family responsible for 
apoptosis in a cell and is localized to the mitochondria. Briefly, members of the Bcl-2 
family either act as apoptosis enablers or apoptosis inhibitors by recruiting proteins from 
the caspase (cysteine-aspartate specific protease) superfamily [70]. The specific role of Bcl-xL 
is to indirectly inhibit the release of cytochrome c, which led to activation of downstream 
“executioner” caspases that trigger cell apoptosis [71]. Bcl-xL has been shown to inhibit 
apoptosis and increase tolerance to environmental stress in various mammalian cell types 
and plant cells (see references for more detailed overview of the Bcl-xL protein) [49, 72, 73, 74]. 
The protein is hypothesized to have similar functionality when introduced to microalgae. 
 
MATERIALS & METHODS 
Sodium butyrate induction of C. reinhardtii wall-deficient strain  
Sodium n-butyrate (>98.5% purity) was from Sigma (Sigma-Aldrich, MO, USA, SKU# 
B5887). It was dissolved in TAP medium as a 1 M stock solution. The stock solution was 
stored at -20 °C and diluted to appropriate concentrations with TAP medium immediately 
before inducing the cells. C. reinhardtii cell wall-deficient strain UTEX 2337 was grown to a 
density of 1 x 107 cells/mL in TAP medium in a T-25 flask. Ten T-25 flasks were seeded at 
a density of 2.5 x 105 cells/mL and grown under normal conditions in TAP media on a 
rotary shaker. Cell counts were taken approximately every 12 hours using Guava Personal 
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Cell Analysis (PCA) Base System (Millipore, USA, Cat# 0500-1090). Samples were diluted 
to appropriate concentrations in Dulbecco's phosphate-buffered saline (DPBS) balanced 
salt solution before counting. 
 
After 45 hours from inoculation, cell densities were around 1 x 106 cells/mL. Cells were 
pelleted by centrifugation at 6,000 x g for 5 min at room temperature. The supernatant was 
disposed and the pellet was resuspended in 10 mL of TAP + varying concentrations of 
sodium butyrate (0 mM, 50 mM, 100 mM, 250 mM, and 500 mM) and grown under 
normal illumination on a rotary shaker. Cells were observed at 100x in a Nikon Eclipse Ti 
microscope at 24 hrs and 48 hrs after sodium butyrate induction.  
 
45 hours after sodium butyrate induction, the cells were harvested by centrifugation at 
6,000 x g for 10 min at room temperature. Cell pellets were stored at -80 °C in the case 
they were needed for further analysis.  
 
Colony PCR of pRelax #6 and #7 
Two C. reinhardtii cell wall-deficient Venus-Bcl-xL (pRelax) strains were provided on TAP + 
1 mg/L bleocin antibiotic plates by Junaid Faruq at the Johns Hopkins University. A small 
quantity of each plate was streaked and resuspended in 50 μL of Tris EDTA (TE) Lysis 
Buffer (0.01 M Tris-HCl (pH 8.0), 0.1 M EDTA). Samples were incubated at 100 °C for 5 
min and subsequently cooled in a fridge to 4 °C. The cells were then centrifuged at 10,000 
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x g for 10 min. The supernatant, now containing extracted DNA and RNA, was collected 
to be used directly to obtain the DNA template for PCR.  
 
PCR reaction was mixed following the Phusion® High-Fidelity DNA Polymerase (New 
England Biolabs, Ipswich, MA #M0530) protocol. 20 μL reaction mixtures were made for 
pRelax #6, pRelax #7, and pRelax plasmid for positive control as follows: 10 μL Nuclease-
free water, 4 μL of 5x Phusion® HF, 0.4 μL of 10 mM dNTPs, 0.6 μL of DMSO, 0.2 μL of 
Phusion® DNA Polymerase, 1 μL of forward primer, 1 μL of reverse primer, and 2 μL of 
genomic DNA (1 μL for plasmid DNA). Forward primer sequence was 5’-
TATCTCGAGATGGTGTCG-3’ and reverse primer sequence was 5’-
ATAAGATCTTCAGGCGCGCTTAC-3’. Samples were placed in an Mastercycler 
Personal PCR machine (Eppendorf, New York, USA) for a total of 34 PCR cycles with 
each cycle set as: 2 min at 95 °C, 20 sec at 95 °C, 45 sec at 52 °C, 1 min at 72 °C, 10 min 
at 72 °C, and ending at 4 °C.  
 
After completion of 34 cycles of PCR, the samples were run in a 1% (w/v) electrophoretic 
gel prepared by 0.5 g of Ultra Pure Agarose (Invitrogen, USA #16500500), 1 μL of 
Ethidium Bromide (10 mg/mL), and 50 mL of DI water. Gene Ruler™ 1 kb DNA ladder 
(Fisher Scientific®, Pittsburg, PA) was used as a reference.  
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Sodium butyrate supplementation of pRelax 
C. reinhardtii cell wall-deficient Venus-Bcl-xL (pRelax) strain were seeded at a density of 5.0 x 
105 cells/mL and grown under normal conditions in TAP media on a rotary shaker. Cell 
counts were taken approximately every 12 hours using Guava Personal Cell Analysis (PCA) 
Base System (Millipore, USA, Cat# 0500-1090). Samples were diluted to appropriate 
concentrations in Dulbecco's phosphate-buffered saline (DPBS) balanced salt solution 
before counting and also Guava Viacount reagent (Millipore, USA, Cat# 4000-0040) for 
more accurate counting and apoptosis analysis.  
 
After around 21 hours from inoculation, cell densities were around 1 x 106 cells/mL. Cells 
were induced with sodium butyrate with the same procedure outlined above for wild-type 
wall-deficient strain. Cells were observed at 100x in a Nikon Eclipse Ti microscope at 24 
hrs and 48 hrs after sodium butyrate induction. Cells were also observed for fluorescence 
under a confocal microscope using a Zeiss LSM 510 Meta confocal microscope at 20x 
magnification. 
 
57 hours after sodium butyrate induction, the cells were harvested by centrifugation at 
6,000 x g for 10 min at room temperature. Cell pellets were washed with DPBS, re-pelleted 
by centrifugation at 6,000 x g and stored at -80 °C for subsequent protein extraction and 
analysis.   
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Extraction of Venus-Bcl-xL protein 
Pelleted cells were taken from -80 °C and defrosted at room temperature. Cells were 
washed in 25 mM K2HPO4/KH2PO4 (pH 7.0) and centrifuged at 500 x g for 10 min. Each 
sample was resuspended in 1 mL of Algae Lysis Buffer (50 mM Tris-HCl (pH 8.0), 500 mM 
NaCl, 0.1% Tween20) with c0mplete, Mini, EDTA-free protease inhibitor cocktail (Roche, 
USA, Cat# 11 836 170 001). The samples were then sonicated on ice for 6 x 30 second 
rounds with 1 minute intervals. Sonication was done at 55 W to avoid foaming. After cell 
lysis, samples were centrifuged at 7,500 rpm. The supernatant was extracted and stored at  -
80 °C to be used later for SDS-PAGE. 
 
Western blot on Venus-Bcl-xL protein 
Protein extracts were taken from -80 °C and defrosted at room temperature. Prepared a 2x 
sample buffer containing 50 μL β-mercaptoethanol (BME) and 950 μL 2x Laemmli sample 
buffer (BioRad, USA, cat# 161-0737). 25 μL of each sample was taken and mixed with 25 
μL of the 2x sample buffer mix and boiled at 100 °C for 5 – 10 min to denature proteins 
to primary and secondary structures. Samples were then loaded into an SDS-PAGE gel and 
run at 130 V for around 75 min in SDS-PAGE running buffer. Gel was transferred onto a 
PVDF membrane by running at 100 V for 75 min in transfer buffer. The membrane was 
blocked for any non-specific binding with a solution of 5% blotting grade dry milk powder 
(BioRad, USA) in PBST (Phosphate-Buffered-Saline-Tween20) by rotating on a shaker for 1 
hr at room temperature. The membrane was washed with PBST. Two membranes were 
treated with two separate primary antibodies: GFP (4B10) Mouse mAB (Cell Signaling 
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Technology, USA, Cat# 2955) and Bcl-XL Rabbit monoclonal antibody (mAb) (Cell 
Signaling Technology, USA, Cat# 2764). The antibodies were diluted at 1:2000 (GFP) and 
1:1000 (Bcl-xL) in 6 mL of PBST with 1% dry milk. The membranes were incubated with 
each primary antibody solution overnight at 4 °C with gentle agitation. The second day, 
membranes were washed three times for 5 minutes each with 10 mL of PBST. Each 
membrane was then incubated with the appropriate HRP-conjugated secondary antibody, 
anti-mouse (GFP) and anti-rabbit (Bcl-xL), with gentle agitation for 1 hr at room 
temperature. The membranes were then developed using a Western-C developing kit 
(BioRad, USA).  
 
RESULTS 
Sodium Butyrate inhibits growth rate and induces apoptosis in wild-type C. reinhardtii 
Wild-type C. reinhardtii cell wall-deficient strain UTEX 2337 was grown in TAP and 
induced with varying concentrations of sodium butyrate after 45 hrs of inoculation. Two 
identical sets of experiments were run in parallel, set A and set B, for comparison. Cell 
counts were done for both sets A and B, every 12 hours and recorded. We found that a 
concentration of 50 mM sodium butyrate slightly inhibited cell growth, while a 
concentration of 100 mM sodium butyrate significantly inhibited cell growth compared to 
the untreated cells. Concentrations of 250 mM and 500 mM were immediately lethal for 





Figure 5a: Effect of sodium butyrate on C. reinhardtii wall-deficient strain (CW 15+) 
UTEX 2337 – Set A. Sodium butyrate induction point was 45 hours after inoculation 

















































































Figure 5b: Effect of sodium butyrate on C. reinhardtii wall-deficient strain (CW 15+) 
UTEX 2337 – Set B. Sodium butyrate induction point was 45 hours after inoculation 












































































The cultures were supplemented with sodium butyrate when the cell density reached about 
1 x 106 cells/mL and when the cells started to enter the exponential growth phase. As 
shown in Figures 5a and 5b above, control cells grew as normal and displayed expected 
exponential growth behavior. Cells treated with 50 mM sodium butyrate also displayed 
exponential growth behavior, and in both cases grew faster than the control group. At 90 
hours, however, the cell densities of the control group and 50 mM group hovered around 
10-13 x 106 cells/mL and the percentage difference between cell densities of 50 mM from 
the control was 7.41% and 4.17% for sets A and B, respectively. In both cases the control 
group began to outgrow the 50 mM group, as the 50 mM group seemed to reach a plateau 
phase. This is within the standard error range for the control group. A concentration of 50 
mM sodium butyrate briefly arrested the cell growth in both cases, although the cells 
seemed to recover within 24 hours. A concentration of 100 mM also arrested cell growth 
upon induction, but the cells appeared to slowly recover after 36 hours and enter a less 
drastic exponential phase compared to the control and 50 mM cells. The percentage 
difference in final cell concentration between cultures treated with 100 mM and 0 mM 
were 60.99% and 64.85% for sets A and B, respectively. Cells treated with 250 mM and 
500 mM sodium butyrate had a significant reversal in cell growth and the cell density of 
the culture quickly dropped below detectable traces.  
 
Also shown in Figures 5a and 5b above, is the effect of sodium butyrate on the viability of 
the cells. Cell viability was above 95% prior to sodium butyrate induction for all cultures, 
indicating that the cells were healthy. A concentration of 50 mM showed a drop in cell 
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viability to 93.77% and 91.97% for sets A and B, respectively, at 66.5 hours (20.5 hours 
post sodium butyrate induction). 100 mM showed a slightly more noticeable decrease as 
viability dropped to 91.7% and 89.8% for sets A and B, respectively. Cell viabilities for 50 
mM and 100 mM slowly recovered after 24 hours, albeit more slowly for 100 mM. Final 
percentage differences for cell viability between control and 50 mM were 1.32% and 2.22% 
for sets A and B, respectively. Final percentage differences for cell viability between control 
and 100 mM were 4.02% and 5.93% for sets A and B, respectively. A concentration of 500 
mM dropped cell viability below 50% within the first hour after induction and the cells 
were completely dead within the first day. A concentration of 250 mM had less immediate 
results, but showed to reduce cell viability to under 20% after 24 hours of induction. The 
cells never recovered, and by the second day the cells were dead.  
 
The effect of sodium butyrate on the algae cells was also visible to the naked eye. The 
suspension cultures grown in T-25 flasks can change in appearance depending on the cell 











Figure 6: C. reinhardtii wall-deficient strain (CW 15+) UTEX 2337 treated with sodium 
butyrate. From left to right: TAP + 0 mM sodium butyrate, TAP + 50 mM sodium butyrate, 
TAP + 100 mM sodium butyrate, TAP + 250 mM sodium butyrate, TAP + 500 mM 
sodium butyrate. (A) 1 day after sodium butyrate supplementation. (B) 2 days after sodium 
butyrate supplementation.  
 
1 day after sodium butyrate induction, cultures induced with 250 mM and 500 mM were 
already beginning to pale. By the second day, the cultures had turned completely white 
indicating that the cells were dead. This is in stark contrast with the dark green color of the 
healthy control cells, which were untreated. The retardation of cell growth for cells treated 
with 100 mM sodium butyrate is visualized as well. After sodium butyrate induction, 
cultures supplemented with 100 mM sodium butyrate maintain a bright green color and 
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only slightly darken in comparison to untreated cultures and cultures grown in 50 mM 
sodium butyrate. 
 
Sodium butyrate induces morphological changes in wild-type C. reinhardtii 
A microscopic view of the cultures also showed interesting implications of the effect of 
sodium butyrate on the algae cell, even within an hour of induction (data not shown). 
Untreated cells and cells treated with 50 mM sodium butyrate appeared to behave 
normally and were very active (data not shown). Cells treated with 100 mM, and above, 
showed significant reduction in mobility and appeared “frozen.” Cells were monitored 




Figure 7: Effect of sodium butyrate on cell growth and morphology 1 day after induction. 
C. reinhardtii wall-deficient strain (CW 15+) UTEX 2337 taken at 20X magnification. (A) 
control 0 mM A (B) control 0 mM B (C) 50 mM A (D) 50 mM B (E) 100 mM A (F) 100 
mM B (G) 250 mM A (H) 250 mM B (I) 500 mM A (J) 500 mM B 
 
 
Cells treated with 50 mM sodium butyrate had a tendency to cluster compared to 
untreated cells. However, cell mobility appeared normal and cells were very active like the 
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cells in the untreated control group. Cells also appeared slightly larger than the control 
group. Cells treated with 100 mM sodium butyrate were minimally active and significantly 
larger than untreated cells. Although cell mobility was reduced significantly, it seemed that 
the cells had slightly recovered some mobility compared to their “frozen” state 1 hour after 
sodium butyrate induction. Cells induced with 250 mM sodium butyrate never recovered 
mobility and had a “shriveled” appearance. Cultures supplemented with 500 mM sodium 
butyrate had no sign of viable cells, and only had cell debris. By zooming in, we took a 






Figure 8: Effect of sodium butyrate on cell growth and morphology 1 day after induction. 
C. reinhardtii wall-deficient strain (CW 15+) UTEX 2337 taken at 20X magnification and 
zoomed. (A) control 0 mM A (B) control 0 mM B (C) 50 mM A (D) 50 mM B (E) 100 mM 
A (F) 100 mM B (G) 250 mM A (H) 250 mM B (I) 500 mM A (J) 500 mM B 
 
A closer look at the individual cells further emphasizes the changes in extracellular 
morphology along with the changes intracellularly. Untreated cells are still relatively small 
at this magnification and a small spot is visible representing the cell nucleus. With the lack 
of quality of intracellular organelles, it is difficult to see the crescent-shaped chloroplast, 
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which makes approximately 40% of the cell. As shown in Figure 8 above, a treatment of 50 
mM is ineffective in changing the morphology for the majority of the microalgae cells, yet 
some of the cells are slightly larger with what also seems to be an enlarged nucleus. The 
changes are significantly more pronounced in cells supplemented with 100 mM. Individual 
cells seem extremely swollen, however intracellular organelles seem intact, especially the 
enlarged nucleus. The cells treated with 250 mM and 500 mM show extensive 
disintegration of the cell membrane and intracellular organelles, leaving only scattered 
fragments of the cell. The cells treated with 250 mM and 500 mM sodium butyrate are also 
in stark contrast with the cells treated with 100 mM as they appear small and shriveled, 
indicating the cells are in the final stages of apoptosis.  
 
The effect of sodium butyrate on a pRelax transgenic C. reinhardtii  
Colony PCR was performed on wall-deficient C. reinhardtii strains pRelax#6 and pRelax#7 




Figure 9: PCR analysis on C. reinhardtii wall-deficient strains pRelax #6 and #7. From 
left to right: M, 1 kb marker; P (+), pRelax plasmid positive control; #6, pRelax strain #6;  
#7, pRelax strain #7.  Expected size of PCR product is 1439 bps.  
 
As shown above in Figure 9, the PCR analysis shows that the pRelax#7 strain has pRelax 
plasmid present in the nuclear genome. The expected band size for the Venus-Bcl-xL gene 
sequence is approximately 1439 bps, and we observe a band at the appropriate location for 
pRelax#7. Interestingly, pRelax#6 did not appear to have the pRelax gene sequence, 
despite its resistance to the bleocin resistance. Thus, pRelax#7 was chosen for the 
subsequent set of sodium butyrate treatment experiments, and is referred to as pRelax from 
this point on.  
 
pRelax cells were exposed to the same set of concentrations of sodium butyrate exposed to 
the wild-type C. reinhardtii cells. 21 hours after inoculation, five identical cultures were 
induced with 0 mM, 50 mM, 100 mM, 250 mM, and 500 mM sodium butyrate. Cell 
counts and cell viability measurements were taken at approximately 12 hour points (see 




Figure 10: Effect of sodium butyrate on C. reinhardtii wall-deficient pRelax strain. 
Sodium butyrate induction point was 22 hours after inoculation (indicated by arrow). (A) 

















































































Figure 11: Effect of sodium butyrate on C. reinhardtii wall-deficient pRelax strain – 
Guava Viacount. Sodium butyrate induction point was 22 hours after inoculation 















































































Figure 10 represents counts and viability measurements taken with the cells diluted in 
DPBS while Figure 11 represents counts and viability measurements taken with the cells 
diluted in Guava Viacount reagent. The red Guava Viacount reagent acts differently by 
permeating the cell walls and staining the cells, separating the viable cells from the cell 
debris. Apoptotic and dead cells absorb the orange dye because of the compromised 
membrane integrity. Therefore, the Guava Viacount reagent is able to separate out the 
apoptotic cells from the viable cells unlike the DPBS.  
 
Both Figure 10 and Figure 11 show similar results for the resistance of the pRelax strain to 
inhibition of cell growth and induction of apoptosis by sodium butyrate. We observed that 
the growth for cells treated with 50 mM sodium butyrate was only slightly inhibited 
immediately after induction. Cells quickly recovered and maintained growth rates similar 
to the control untreated cells. Cell treated with 100 mM sodium butyrate experienced a 
slight shock to sodium butyrate induction, but also quickly recovered and exhibited only a 
slightly slower growth rate than the control group. Eventually, the cell densities converge at 
around 12 x 106 cells/mL for untreated, 50 mM and 100 mM cells. When measured with 
Guava Viacount reagent, the final cell density between the control, 50 mM, and 100 mM 
vary only by approximately 0.3%.  
 
Concentrations above 250 mM of sodium butyrate quickly induced apoptosis in the 
pRelax cells, which is shown by the sharp drop in cell density and cell viability upon 
sodium butyrate induction.  In the case of the cells treated with 50 mM and 100 mM 
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sodium butyrate, the cell viability never drops below 97% when measured with DPBS and 
93% when measured with the Guava Viacount reagent. This preservation in cell viability is 
despite the slightly slower growth rates in cells treated with 100 mM sodium butyrate. 
Interestingly, when measured with Guava Viacount reagent, we observed that the cells 
treated with 50 mM and 100 mM sodium butyrate exhibited higher viability 57 hours from 
induction. The final viability for 50 mM and 100 mM was higher from control by 11.41% 
and 11.81%, respectively. Using the Guava Viacount reagent, we are also able to measure 
apoptotic cells from the dead cells, thus giving a more accurate representation of apoptotic 
behavior (see Figure 12).  
 
 
Figure 12: Percent apoptotic of C. reinhardtii wall-deficient pRelax cells after sodium 






























Using Guava Viacount reagent, we observed that the cells were slightly more apoptotic for 
several hours immediately after sodium butyrate induction. However, within 22 hours the 
cells seemed to recover and maintain a low level of apoptotic behavior. The untreated 
pRelax cells were around 3% apoptotic until about 80 hours after inoculation (or 57 hours 
after sodium butyrate induction) when the culture became 13% apoptotic. This was in 
stark contrast to the cultures treated with 50 mM and 100 mM sodium butyrate as their 
final apoptotic percentage 80 hours after inoculation (or 57 hours after sodium butyrate 
induction) were 3.25% and 2.85%, respectively. The pRelax cultures treated with 50 mM 
and 100 mM sodium butyrate were 75% and 78% less apoptotic than untreated pRelax 
cells, respectively.  
 
As shown previously with the wild-type C. reinhardtii wall-deficient cells, the effect of 
sodium butyrate on cell growth and cell viability can also be observed by looking at the 
culture with the naked eye (see Figure 13). 
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Figure 13: C. reinhardtii wall-deficient Venus-Bcl-XL strain (pRelax) treated with sodium 
butyrate. From left to right: TAP + 0 mM sodium butyrate, TAP + 50 mM sodium butyrate, 
TAP + 100 mM sodium butyrate, TAP + 250 mM sodium butyrate, TAP + 500 mM 
sodium butyrate. (A) 0 hours after sodium butyrate supplementation. (B) 12 hours after 
sodium butyrate supplementation. (C) 24 hours after sodium butyrate supplementation. (D) 
48 hours after sodium butyrate supplementation. 
 
From Figure 13 above, we can observe the progressive growth of the cells treated with 0 
mM, 50 mM and 100 mM sodium butyrate. We also see how addition sodium butyrate at 
concentrations over 250 mM is lethal to the cultures by the immediate blanching of the 
cultures treated with 250 mM and 500 mM. The slightly slower growth rate of the culture 
treated with 100 mM can be seen at 12 hours and 24 hours after sodium butyrate 
induction, along with the convergence of cell densities at 48 hours post induction. 
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Fluorescent and confocal imaging of sodium butyrate induced pRelax cells 
24 hours after sodium butyrate induction, samples were taken for fluorescent imaging to 
observe any enhanced fluorescence from the Venus-Bcl-xL fusion protein. At this point, 
cultures treated with 250 mM and 500 mM sodium butyrate were already dead and thus 




Figure 14: C. reinhardtii wall-deficient Venus-Bcl-XL strain (pRelax) 1 day after sodium 
butyrate induction. (A) – (B) is TAP + 0 mM sodium butyrate. (C) – (D) is TAP + 50 mM 
sodium butyrate. (E) – (F) is TAP + 100 mM sodium butyrate. (A), (D), (E) are images taken 
with Brightfield filter and (B), (D), (F) are images taken with a FITC filter. 
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As shown in Figure 14 above, the cells treated with 50 mM and 100 mM sodium butyrate 
exhibit changes in cell morphology as well. The induced cells are larger, with preserved 
membrane. In the case of the pRelax cells, even untreated cells had very limited mobility or 
flagellar action (results not shown), so sodium butyrate effect on cell mobility is not easily 
observed. We applied a FITC filter to excite the Venus protein, to observe any indication 
of the protein expression. The yellow fluorescent protein reporter, Venus, fused to the Bcl-
xL has an excitation wavelength of 515 nm and an emission wavelength 528 nm [75]. As 
shown in Figure 14 above, the cells do not show high levels of fluorescence. What little 
fluorescence that is seen is possibly the cell’s auto-fluorescence due to the chlorophyll. 
Chlorophyll has a slight excitation at wavelengths close to 500 nm, which is within the 
range of the FITC excitation.  
 
Western Blot and protein analysis of recombinant Venus-Bcl-xL 
Due to difficulty in verifying expression of the Venus-Bcl-xL protein by fluorescence, we 
proceeded to do protein extraction and analysis by western blotting. The size of Venus is 
approximately 27 kDa, and the size of Bcl-xL is about 30 kDa. Therefore, the expected band 
lengths were approximately 57 kDa for a fusion protein.  After protein extraction and 
western blot, we were unable to observe any bands at the expected locations, while the 




Varying concentrations of sodium butyrate were added to suspension cultures of wall-
deficient C. reinhardtii 45 hours after inoculation. In a preliminary experiment to 
determine the range of sodium butyrate supplementation, 1 mM, 5 mM, 10 mM, 25 mM, 
and 50 mM sodium butyrate was added to the cell cultures after 45 hours of growing under 
normal conditions in TAP media on a rotary shaker in T-25 flasks. Cell counts and 
microscopy indicated no change in growth behavior and cell morphology at concentrations 
below 50 mM of sodium butyrate (data not shown). Thus, a subsequent study was done 
using concentrations of 50 mM, 100 mM, 250 mM, and 500 mM sodium butyrate. The 
initial range of sodium butyrate concentrations used in the preliminary experiments was 
based on similar inductions done in transgenic tomato cells. The wild-type wall-deficient C. 
reinhardtii cells were surprisingly tolerant to concentrations of sodium butyrate that would 
otherwise be lethal for mammalian cells and plant cells that have been so far tested. This 
may be explained by the fact that simple n-butyrate is rapidly metabolized in plant cells 
during photoautotrophic growth [69].  
 
Sodium butyrate induces changes in cell growth and cell morphology in C. reinhardtii 
We observed cell growth inhibition of wild-type C. reinhardtii cells induced by sodium 
butyrate at concentrations of 50 mM and 100 mM. These concentrations induced 
apoptosis in the cells as indicated by decreases in cell viability and also changed the 
appearance of the cells significantly. Although the exact mechanism behind these 
observations cannot be concluded through this study, the results are similar to observations 
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seen in similar studies with mammalian and plant cells. In transgenic tomato cells, 
treatment with sodium butyrate up-regulated 4 growth-arrest-specific proteins and down 
regulated two cell division proteins. There is high likelihood that sodium butyrate induces 
a similar mechanism in mammalian cells and microalgal cells. Similar to many documented 
results of morphological changes in mammalian cells induced by sodium butyrate, we 
observed a significant enlargement of the cells. Higher concentrations of sodium butyrate 
could also lead to higher osmotic pressure, which could be a possible factor in the 
appearance of swollen cells. The cells may also be going through the cell division or 
apoptotic stage of their cell cycle, although these would be reflected in the cell growth 
curves or apoptosis graphs.  
 
Expression and function of recombinant Venus-Bcl-xL protein 
The treatment of the pRelax strain with sodium butyrate produced interesting results. 
There was significantly less inhibition of cell growth compared to the wild-type cells at the 
same concentration of sodium butyrate. Despite the observed tolerance to the apoptotic 
inducing effects of sodium butyrate, the pRelax cells did not have noteworthy levels of 
fluorescence or protein. PCR also confirmed the presence of the vector sequence in the 
nuclear genome. Some explanations for the lack of observed fluorescence is the extremely 
low expression of the protein along with the localization of the protein to the 
mitochondria. The mitochondria is a small organelle located near the nucleus, so with 
observation at 20x using a fluorescent microscope would make it difficult to see clear 
fluorescence to begin with. The most probable explanation for the absence of positive 
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bands from the western blot is the low expression of the target recombinant protein along 
with the relatively low quantities of cells harvested. Although the density was at about 12 x 
106 cells/mL, only around 10 mL were cultured. Since the expected expression level of 
Venus-Bcl-xL is low, the culture should be scaled-up for a subsequent study with 
supplementation at the same range of sodium butyrate concentrations, and then harvested 
for protein extraction.  
 
Another possibility for lack of observed expression is the limitation of the protein 
extraction method. Although we utilized a sonication method with cell lysis buffer and 
protease inhibitors, it is possible that the protein was either degraded by the sonication, or 
never fully extracted due to its localization to the mitochondria. In this event, the cell lysate 
should also be analyzed for the possible presence of Venus-Bcl-xL protein. 
 
Although the expression of the protein could not be verified with fluorescence or western 
blotting, the results of tolerance and resistance to apoptosis shown in cell growth curves 
and viability charts indicate the presence and functionality of the Venus-Bcl-xL protein. 
While the level of expression may be low, there seems to be an enhancement of anti-
apoptotic behavior in pRelax cells treated with 50 mM and 100 mM sodium butyrate. It 
can be hypothesized that this is in fact due to an up-regulation of transgene expression 




For decades, the effect of sodium butyrate has been studied in mammalian cells and plant 
cells. There has been particular interest in the transgene expression enhancing effects of 
sodium butyrate in these systems. Surprisingly, almost no literature or documentation is 
available on the application of sodium butyrate in microalgae systems. This study explored 
the effects of exposing microalgae C. reinhardtii to sodium butyrate in varying 
concentrations ranging from 0 mM to 500 mM and observing the possible changes in cell 
growth, cell morphology and transgene expression.  
 
Green microalgae C. reinhardtii seems inherently tolerant to the expected effects of sodium 
butyrate, and thus changes in cell growth and morphology were observable at 
concentrations above 50 mM, over ten times the lethal concentration for most tested 
mammalian cells. However, at concentrations of 50 mM and 100 mM sodium butyrate, we 
observed inhibition of cell growth along with induction of apoptosis. At these 
concentrations the cells appeared larger and rounder, with seemingly enlarged nuclei. 
Concentrations above 250 mM were deadly to the cells and quickly induced apoptosis as 
observed by cell growth curves, viability measurements, and microscopy.  
 
A transgenic cell line of C. reinhardtii expressing a mammalian anti-apoptotic Venus-Bcl-xL 
fusion protein was also treated with a range of sodium butyrate concentrations. These cells 
were significantly tolerant to the sodium butyrate stress and exhibited resistance to 
apoptosis compared to the wild-type strain of C. reinhardtii. Even within the same cell-line, 
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pRelax cells treated with 50 mM and 100 mM sodium butyrate were 75% and 78% less 
apoptotic than untreated pRelax cells, respectively. Although protein expression was not 
confirmed by western blot or fluorescence microscopy, these results suggest a possible 






































SUMMARY & FUTURE APPLICATION 
 
The potential for microalgae as a standard molecular farming platform is promising due to 
its high growth rate and relatively scalability. The versatility of the nuclear genome in 
performing post-transcriptional, post-translational modifications, and post-translational 
targeting to specific intracellular organelles make nuclear expression from microalgae a 
powerful potential alternative to current expression systems. Unfortunately, due to the 
high levels of transgene silencing frequently experienced in the nuclear genome, microalgae 
is still far from realizing its full potential as a revolutionary recombinant protein expression 
platform. 
 
Much of the efforts in tackling low expression of recombinant proteins from the nucleus 
are focused on optimizing design at the genetic level with promoters, codon optimization, 
and plasmid designs. This study outlines a potential avenue focused on the downstream 
side of process design through sodium butyrate supplementation of the suspended 
microalgal cultures. Sodium butyrate has been shown to induce apoptosis in mammalian 
cell lines and inhibit cell growth in various mammalian cells and plant cells. In this study, 
these changes were similarly observed in microalgae upon sodium butyrate induction at 
concentrations of 50 mM and 100 mM. Induced apoptosis and inhibition of cell growth 
was reversible over time and the cells were able to recover after 24 – 48 hours. Along with 
inducing apoptosis and inhibition of cell growth, sodium butyrate is known to enhance 
transgene expression in various mammalian cell lines and plant cell lines. Although similar 
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results cannot be readily concluded from this study, we observe the enhanced functionality 
of an anti-apoptotic recombinant Venus-Bcl-xL fusion protein in a transgenic strain of 
microalgae C. reinhardtii treated with 50 mM and 100 mM sodium butyrate. The use of an 
expressed Bcl-xL protein to resist the induction of apoptosis of sodium butyrate treated cells 
has interesting implications for a powerful combination system that integrates the powerful 
transgene enhancing capabilities of sodium butyrate supplementation with the anti-
apoptotic function of Bcl-xL to negate the side-effects of sodium butyrate exposure. The 
model system would have the target protein of interest co-expressed with a Bcl-xL protein. 
Sodium butyrate supplementation would then, in concept, induce higher expression of 
both proteins. Although it is preliminary, this study shows promising signs of the 
applicability of using a sodium butyrate, and the coupled effect of an anti-apoptotic Bcl-xL 
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  0mM 50mM 100mM 250mM 500mM 
Time (hours) 
0 0.5 0.5 0.5 0.5 0.5 
21 1.376417068 1.416597624 1.045854585 1.052582223 1.924819092 
24.5 1.501912503 1.11727886 0.827692677 0.592665881 0.146044403 
30.5 2.258380863 1.391900577 0.783402326 0.173276148 0.004568027 
44.5 5.023428777 5.101885395 3.183771287 0 0 
56 9.864717 9.395252527 4.930937959 0 0 
 
67.5 11.45165777 13.76014581 10.17741211 0 0 
 







  0mM 50mM 100mM 250mM 500mM 
Time (hours) 
0 0.5 0.5 0.5 0.5 0.5 
21 1.36503896 1.39872821 1.02845067 1.040920817 1.898534543 
24.5 1.477646627 1.099361147 0.814113503 0.433997633 0.001709057 
30.5 2.2243525 1.374727337 0.767165417 0.046596847 0.00006715 
44.5 4.921574 5.055948 3.15401625 0 0 
56 9.747512667 9.305599 4.883101 0 0 
 
67.5 11.26342833 13.64458933 10.13233833 0 0 
 
79.5 10.96120967 13.89254367 10.74133933 0 0 
 
 
Standard Error (Total Cells) 
 
  0mM 50mM 100mM 250mM 500mM 
Time (hours) 
0 0 0 0 0 0 
21 0.06983315 0.100568029 0.054384683 0.046201862 0.071236527 
24.5 0.04163329 0.071682545 0.015197694 0.015914345 0.00162459 
30.5 0.039566757 0.038661228 0.011744203 0.005121146 0.004568027 
44.5 0.124263857 0.153517576 0.061045913 0 0 
56 0.299822794 0.548260386 0.114020435 0 0 
 
67.5 0.457935328 0.329683759 0.594306219 0 0 
 








Standard Error (Viability) 
 
  0mM 50mM 100mM 250mM 500mM 
Time (hours) 
0 0 0 0 0 0 
21 0.176383421 0.145296631 0.504424865 0.290593263 0.32829526 
24.5 0.435889894 0.1 0.218581284 0.721880261 0.218581284 
30.5 0.2081666 0.260341656 0.260341656 0.721880261 0.49 
44.5 0.272845092 0.152752523 0.033333333 0 0 
56 0.346410162 0.185592145 0.218581284 0 0 
 
67.5 0.145296631 0.145296631 0.218581284 0 0 
 




TOTAL CELLS/mL (GUAVA) 
Cells/mL 
  0mM 50mM 100mM 250mM 500mM 
0 500000 500000 500000 500000 500000 
21 1376417.068 1416597.624 1045854.585 1052582.223 1924819.092 
24.5 1165300.421 955438.9414 748240.1482 675815.6534 510393.3333 
30.5 1937180.642 1295515.982 699299.7585 237458.8499 30283.33333 
44.5 4603020.187 5124294.584 2819384.615 0 0 
56 9153378.996 10197592.82 4232535.501 0 0 
67.5 13214317.24 12055832.48 7663538.079 0 0 






  0mM 50mM 100mM 250mM 500mM 
Time (hours) 
0 100 100 100 100 100 
21 99.16666667 98.73333333 98.33333333 98.86666667 98.63333333 
24.5 95.55 95.45 94.7 56.7 0.9 
30.5 96.6 93.8 93 27.75 0.5 
44.5 97.5 97.1 97.5 3.3 0.2 
56 97.55 97.8 97.15 0 0 
 
67.5 97.1 98.3 97.95 0 0 
 












PERCENT APOPTOTIC  (GUAVA) 
  0mM 50mM 100mM 250mM 500mM 
0 
     21 
     2 3.55 4.45 4.9 26 28.5 
8 2.7 5.85 6.5 30.9 2.5 
22 2.45 2.55 2.35 59.9 2.4 
33.5 2.45 2.15 2.7 
  45 2.7 1.65 1.95 
  57 13 3.25 2.85 
   
 
 
Standard Error (Total Cells) 
 
  0mM 50mM 100mM 250mM 500mM 
Time (hours) 
0 0 0 0 0 0 
21 0.06983315 0.100568029 0.054384683 0.046201862 0.071236527 
24.5 0.038164281 0.000815803 0.011957735 0.022245411 0.023312792 
30.5 0.067330676 0.016017735 0.034811485 0.01039736 0.024726238 
44.5 0.047328991 0.178601923 0.064527515 0 0 
56 0.418575205 0.464268317 0.078550426 0 0 
 
67.5 0.65545851 0.830919968 0.000298263 0 0 
 




Standard Error (Viability) 
 
  0mM 50mM 100mM 250mM 500mM 
Time (hours) 
0 0 0 0 0 0 
21 0.21602469 0.145296631 0.504424865 0.290593263 0.32829526 
24.5 0.15 0.040824829 0.163299316 0.816496581 0 
30.5 0.5 0.816496581 0.163299316 0.816496581 0.163299316 
44.5 0.163299316 0.40824829 0 0.081649658 0.081649658 
56 0.530722778 0.163299316 0.204124145 0 0 
 
67.5 0.163299316 0.163299316 0.122474487 0 0 
 
79.5 0.40824829 0.40824829 0.44907312 0 0 
 
